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Background
Mevalonate kinase deficiency (MKD) is a rare periodic fever syndrome with autosomal 
recessive inheritance that is caused by a mutation in the MVK gene encoding meva-
lonate kinase (MK) (Esposito et al. 2014). MKD patients suffer from autoinflammatory 
Abstract 
TAK-475 (lapaquistat acetate) and its active metabolite-I (TAK-475 M-I) inhibit squalene 
synthase, which catalyzes the conversion of farnesyl diphosphate (FPP) to squalene. 
FPP is a substrate for synthesis of other mevalonate-derived isoprenoids (MDIs) such 
as farnesol (FOH), geranlygeranyl diphosphate (GGPP), and geranylgeraniol. In patients 
with MKD, a rare autosomal recessive disorder, defective activity of mevalonate kinase 
leads to a shortage of MDIs. MDIs especially GGPP are required for prenylation of 
proteins, which is a posttranslation modification necessary for proper functioning of 
proteins like small guanosine triphosphatases. Malfunction of prenylation of proteins 
results in upregulation of the inflammatory cascade, leading to increased production 
of proinflammatory cytokines like interleukin-1β (IL-1β), eventually leading to episodic 
febrile attacks. In vitro, TAK-475 M-I incubation in a concentration dependent manner 
increased levels of FPP, GGPP, and FOH in human monocytic THP-1 cells. In subsequent 
experiments, THP-1 cells or human peripheral blood mononuclear cells (PBMCs) were 
incubated with simvastatin, which inhibits hydroxymethylglutaryl-coenzyme A reduc-
tase and thereby decreases levels of the precursors of MDIs, leading to the depletion 
of MDIs as expected in MKD patients. Increased levels of GGPP and FPP attenuated 
lipopolysaccharide (LPS)-induced IL-1β production in THP-1 cells and human PBMCs 
in statin-treated conditions. The MDIs also significantly reduced the damaged cell ratio 
in this active MKD-like condition. Moreover, TAK-475 M-I directly inhibited LPS-induced 
IL-1β production from statin-treated THP-1 cells. These results show anti-inflammatory 
and cytoprotective effects of MDIs via TAK-475 M-I treatment in statin-treated immune 
cells, suggesting that possible therapeutic effects of TAK-475 treatment in MKD patients.
Keywords: Squalene synthase inhibitor, MDIs, Mevalonate kinase deficiency patients, 
Anti-inflammatory effects, Cytoprotective effects
Open Access
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and 
indicate if changes were made.
RESEARCH











Page 2 of 14Suzuki et al. SpringerPlus  (2016) 5:1429 
disorders characterized by recurrent episodes of fever (Bader-Meunier et  al. 2011) 
accompanied by painful lymphadenopathy; gastrointestinal symptoms, and so on (van 
der Hilst et al. 2008; van der Burgh et al. 2013; Ter Haar et al. 2013; Lainka et al. 2012). 
The MK gene mutation causes a dramatic decrease in MK enzymatic activity. MK con-
verts mevalonic acid to mevalonate-5 phosphate, which is the precursor for the synthesis 
of a range of MDIs, including FPP, FOH, GGPP, GGOH, ubiquinones, and dicarboxylic 
acids (DCAs) (van der Burgh et al. 2013; Tricarico et al. 2014; Hubner et al. 1993; Xu 
et  al. 2015). Consequently, MDI levels in MKD patients are reported to be decreased 
(Hubner et al. 1993). MDIs play a crucial role in the regulation and production of a range 
of cytokines, and decreased MDI levels are implicated in increases in pro-inflammatory 
mediators, including interleukin-1β (IL-1β), interleukin-6, C-reactive protein (CRP), and 
monocyte chemotactic protein-1 (Kostjukovits et al. 2015; Mandey et al. 2006; Marcuzzi 
et al. 2013). Moreover, an increased production of inflammatory cytokines by peripheral 
blood mononuclear cells (PBMCs), including monocytes, has been suggested as a central 
mechanism in the inflammatory phenotype of MKD.
TAK-475 (also termed as lapaquistat acetate) is a benzoxazepine derivative squalene 
synthase inhibitor (SSI) (Miki et al. 2002; Nishimoto et al. 2003), which was developed 
by Takeda Pharmaceutical Company Limited and has proceeded to clinical Phase III 
in hyperlipidemia indication (Stein et al. 2011). In this Phase III clinical trial, the dose-
dependent cholesterol-lowering efficacy via inhibition of squalene synthase by TAK-475 
was indeed observed with occasional liver enzyme elevation, ultimately leading to the 
discontinuation of clinical development in 2007 based on the risk–benefit evaluation. 
Preclinical pharmacokinetic studies have demonstrated that most of the dosed TAK-
475 is quickly hydrolyzed to TAK-475 M-I during the in vivo absorption process (Miki 
et al. 2002) as shown in Scheme 1. We hypothesized the inhibition of squalene synthase 
by TAK-475 could increase the level of MDIs in MKD patients (Scheme 2). Increased 
MDIs would in turn attenuate the unregulated inflammatory cascade and eventually 
lead to the overall improvement of their clinical symptoms. In support of our hypoth-
esis, it has been reported that another squalene synthase inhibitor, zaragozic acid A, on 
skin fibroblasts from MK-deficient patients has shown increased residual MK enzyme 
TAK-475                                      TAK-475 M-I 
hydrolysis
Scheme 1 Chemical structures of TAK-475 and TAK-475 M-I. TAK-475, 1-{[(3R,5S)-1-(3-Acetoxy-
2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl}
piperidine-4-acetic acid (C33H41ClN2O9) is quickly hydrolyzed to TAK-475 M-I during the in vivo absorption 
process as shown in Scheme 1
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activity, indicating that treatment of MKD with the supply of MDIs may prove beneficial 
in the prevention and treatment of the symptoms of MKD (Schneiders et al. 2006). In 
this report we have investigated the effects of TAK-475 M-I on the levels of MDIs as well 
as anti-inflammatory properties in MKD-like immune cells in order to evaluate whether 
TAK-475 could confer clinical benefit in patients with MKD.
Methods
Chemicals
TAK-475  M-I (T-0091485, Lot No. X000000090965) was synthesized in Chemical 
Development Laboratories of Takeda Pharmaceutical Company Limited. For internal 
control, GGPP (Lot No. E00166-66) and FPP (Lot No. MJB-E00026-28) were purchased 
from Echelon Biosciences. GGOH (Lot No. 2598758) was purchased from LKT Labora-
tories. FOH (Lot No. MKBK0393 V) was purchased from Sigma-Aldrich. LPS (Lot No. 
PDM3922) were purchased from Wako Pure Chemical Industries.
Cell cultures and treatments
THP-1 human monocytic cells (ATCC No. TIB-202) were obtained from American 
Type Culture Collection (ATCC, Manassas, VA, USA). THP-1 cells were grown in RPMI 
1640 supplemented with 10  % FBS (Life Technologies) and penicillin–streptomycin 
(Wako Pure Chemical Industries) at 37 °C, 5 % CO2 in humidified incubator(Liao et al. 
2013). THP-1 cells were stimulated with various concentrations of TAK-475 M-I for 48 h 
(Fig. 1). Or THP-1 cells were treated with 4 μmol/L of simvastatin for 24 h, following 
stimulated with 10 ng/mL of LPS in the presence of MDIs at concentrations from 0.001 
Scheme 2 Mechanism of action of TAK-475 and TAK-475 M-I. Simply explaining, TAK-475 and TAK-475 M-I 
accumulate MDIs, which are strongly decreased in MKD patients, and the increased MDIs stop inflammation 
via blocking the release of inflammatory cytokines as shown in Scheme 2
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to 10 μmol/L for additional 24 h (Figs. 2, 3). Or THP-1 cells were treated with simvas-
tatin (3 or 4 μmol/L) for 48 h in the presence of TAK-475 M-I (150 or 1000 nmol/L), 
following stimulated with LPS (0.1, 1 or 10  ng/mL) for additional 24  h (Fig.  6). Then, 
supernatants or cells pellets were collected and stored at −80  °C before the measure-
ment of the concentrations of IL-1β or MDIs.  
Human PBMCs isolation and treatment
Human whole blood was collected from 3 healthy volunteer donors. All human healthy 
volunteer donors have provided their informed consent for participation, in compliance 
with all Principles of the Declaration of Helsinki. This study was approved by Independ-
ent Ethics Committee of Takeda Pharmaceutical Company Limited, Kanagawa, Japan. 
According to the standard Ficoll-Paque density gradient centrifugation methods, human 
PBMCs were collected and grown in 96 well plates (2 × 105/well) with culture medium 
at 37 °C, 5 % CO2 in humidified incubator. Human PBMCs were treated with 3 μmol/L of 
Fig. 1 FPP, FOH and GGPP but not GGOH were increased in a dose-dependent trend in 48 h treatment of 
TAK-475 M-I. THP-1 cells were stimulated with various concentrations of TAK-475 M-I for 48 h. FOH, FPP, GGOH 




























Fig. 2 GGPP, FPP and GGOH inhibited LPS-stimulated IL-1β production in MKD-like THP-1 cells. IL-1β protein 
concentration in culture supernatants of LPS-stimulated MKD-like THP-1 monocyte cells was measured using 
ELISA. Data are represented as mean ± SD, n = 3
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simvastatin for 24 h. Then, the cells were stimulated with 200 ng/mL of LPS in the pres-
ence of 10 μmol/L of GGPP or FPP for additional 24 h (Figs. 4, 5).
Measurements of the concentration of MDIs
FOH, FPP, GGOH and GGPP in cells were quantified by LC–MS/MS by Sumika Chemi-
cal Analysis Service., and the lowest detection limit was 0.008 μg/1.5 × 106 cells, and the 
highest detection limit was 2 μg/1.5 × 106 cells. Values below the detection limit were 
presumed to be 0.008 μg/1.5 × 106 cells, and values higher the detection limit were pre-
sumed to be 2 μg/1.5 × 106 cells.
Extraction and enzymatic hydrolysis
In cell samples (1.5 × 106 cells), 100 μL of 8 % KOH ethanol solution was added and the 
samples were incubated at 80 °C for 2 h. The samples were agitated during the incubation 
to disintegrate the plasma and cell efficiently. The obtained solution was cooled down to 
ambient temperature and centrifuged at 3000 rpm for 5 min. To the obtained superna-
tant (50 μL), 10 μL of n-pentadecanol (I.S.) solution (1 μg/mL) and 2 mL of 1.5 mol/L 
Tris–HCl buffer (pH8.6) containing 0.25  mol/L MgCl2 were added. FOH, GGOH and 
I.S. in the solution were extracted with 5 mL of n-hexane/ethanol (98.5:1.5, v/v, 2 times), 
and the obtained supernatant by centrifugation at 3000 rpm for 5 min was evaporated 
Fig. 3 MDIs significantly inhibited cytotoxicity measured by DCR in LPS-stimulated MKD-like THP-1 cells. 
Damaged cell ratio was measured in triplicates using ToxiLight bioassay kit (Lonza, Basel, Switerland) and 
expressed the ratio of AK activity from AK-releasing cells against that from total cells. Data are represented 
as mean + SD, n = 3. The cytotoxicity of LPS was evaluated by a Student’s t-test with significance set at 
###P < 0.001 (versus 0 μmol/L of MDI and 0 ng/mL of LPS). The dose-dependent effects of MDIs in LPS-stimu-
lated MKD-like THP-1 cells were evaluated by a two-tailed Williams’ test with significance set at **P < 0.01 and 
***P < 0.001 (versus 0 μmol/L of MDI and 10 ng/mL of LPS)
Page 6 of 14Suzuki et al. SpringerPlus  (2016) 5:1429 
Fig. 4 GGPP and FPP inhibited LPS-stimulated IL-1β production in MKD-like human PBMCs. IL-1β protein 
concentration in culture supernatants of LPS-stimulated MKD-like PBMCs in the presence of MDIs (both: 
10 μmol/L) was measured in triplicates using ELISA. Data are represented as mean + SD, n = 3. Statistical 
significance was determined by a Dunnett’s test. ***P < 0.001 versus 0 μmol/L of MDI with LPS
Fig. 5 GGPP and FPP showed a tendency to have cytoprotective effects in LPS-stimulated MKD-like human 
PBMCs. Damaged cell ratio (DCR) was measured using ToxiLight bioassay kit (Lonza) and expressed the ratio 
of AK activity from AK-released cells against that from total cells. Data are represented as mean + SD, n = 3. 
The cytotoxicity of simvastatin and LPS in PBMCs was evaluated by a Dunnett’s test with significance set at 
#P < 0.05 and ##P < 0.01 (versus 0 μmol/L of MDI without simvastatin and LPS). The effects of GGPP and FPP in 
LPS-stimulated MKD-like PBMCs were evaluated by a Dunnett’s test. *P < 0.05 (versus 0 μmol/L of MDI with 
LPS and simvastatin)
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under a stream of N2 gas. FPP and GGPP were quantified as FOH and GGOH, respec-
tively (Ctotal) together with free FOH and GGOH (Cfree) after enzymatic hydrolysis using 
alkaline phosphatase. The concentrations of FPP and GGPP were calculated by subtract-
ing the Cfree from Ctotal. If the calculated value is negative, the concentration is described 
as “0.00”. For enzymatic hydrolysis, alkaline phosphatase (1 unit) were added to 8 % KOH 
sample solution (plasma: 20 μL, cell: 50 μL) with 2 mL of 1.5 mol/L Tris–HCl buffer (pH 
8.6) containing 0.25 mol/L MgCl2, and samples were incubated at 37 °C for 2 h. The fol-
lowing extraction procedure was the same as described above.
Derivatization of FOH and GGOH
To above extracts, 250  μL of 3-nitrophthalic anhydride pyridine solution (10  mg/
mL) was added, and the samples were incubated at 70 °C for 30 min. After the incu-
bation, pyridine was evaporated under a stream of N2 gas. The residue was dissolved 
in 200 μL of methanol, and 500 μL of 50 mmol/L phosphate buffer (pH3) was added 
to the methanol solution. The derivatives of FOH, GGOH and I.S. (FOH-NPA, 
GGOH-NPA and I.S.-NPA respectively) in the solution were extracted with 5  mL 
of n-hexane. n-hexane extract was concentrated under the N2 gas, the residue was 
dissolved in a mixture of methanol/water/acetic acid (75:25:0.1, v/v/v) (200 μL) for 
LC–MS/MS analysis. A 10 μL portion of the solution was injected into the LC–MS/
MS system.
LC–MS/MS
FOH-NPA, GGOH-NPA, and I.S.-NPA were analyzed using a LC-10A system (Shi-
madzu Corp., Kyoto, Japan) coupled with API4000 (AB Sciex Pte. Ltd., Ontario, Can-
ada). The column was used Symmetry Shield RP8 (2.1 mm ID × 150 mm L., Waters, 
MA, USA). A mixture of acetonitrile/water/acetic acid (90:10:0.1, v/v/v) was used as 
a mobile phase at a flow rate of 0.2 mL/min. The conditions of turbo ion spray inter-
face and mass spectrometer were operated under the following conditions: ionization 
polarity, negative; ion spray voltage, −4.5 kV; turbo probe temperature, 425 °C; curtain 
gas flow, 30 L/min (N2); nebulizer gas flow, 40 L/min (air); heater gas flow (N2), 70 L/
min; and collision gas pressure (N2), 10  mPa. Spectra were obtained in the selected 
reaction monitoring (SRM) mode. The monitoring ions and collision energy were 
shown as follows:
Peaks on the chromatogram were identified based on the retention time and the mass-
to-charge ratio (m/z) of the monitoring ions. The concentrations of FOH and GGOH 
were determined from the peak area of FOH and GGOH using the absolute calibration 
curve method because I.S. peak area was varied widely. The calibration curves of FOH 
and GGOH were linear in the spiked concentration range from 0.008 to 0.8 μg/mL.
FOH-NPA m/z414 to m/z 166 − 20 eV
GGOH-NPA m/z 482 to m/z 166 − 22 eV
I.S.-NPA m/z 420 to m/z 166 − 22 eV
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Measurements of IL‑1β protein concentration by ELISA and statistics
The concentration of IL-1β protein in culture supernatants was measured in triplicates 
using ELISA kits (R&D Systems, Minneapolis, MN, USA), according to the manufac-
turer’s instruction. The lower limit of quantification (LLOQ) was 7.8 pg/mL, and meas-
urement values below the LLOQ were presumed to be 7.8 pg/mL. Data are presented 
as the mean ± SD. IC50 values were calculated by GraphPad Prism ver.5 from the data 
expressed as % of IL-1β protein concentration. The mean IL-1β concentration of vehicle 
control without LPS was set as the 0  %, and the mean IL-1β concentration of vehicle 
control with LPS was set as the 100  %. For the analysis of inhibitory effects of GGPP 
and FPP on LPS-stimulated IL-1β production, statistical significance was determined 
by a Dunnett’s test. P < 0.05 was considered statistically significant (Fig. 4). For dose–
response analysis of inhibitory effect of TAK-475 M-I on LPS-stimulated IL-1β produc-
tion, statistical significance was determined by a one-tailed Williams’ test. P < 0.025 was 
considered statistically significant (Fig. 6).
Cytotoxicity assay and statistics
Cytotoxicity assay was conducted using ToxiLight bioassay kit (Lonza, Basel, Switzer-
land), a bioluminescent, non-destructive cytolysis assay kit designed to measure the 
release of the enzyme, adenylate kinase (AK), from damaged cells. Damaged cell ratio 
(DCR) was estimated by dividing AK activity from AK-released cells by that from total 
cells. Data are represented as the mean + SD (n = 3). The cytotoxicity of LPS was evalu-
ated by a Student’s t test, and the dose-dependent effects of MDIs in LPS-stimulated 
MKD-like THP-1 cells were evaluated by a two-tailed Williams’ test. In both tests, 
Fig. 6 TAK-475 M-I inhibited LPS-stimulated IL-1β production in MKD-like THP-1 cells. IL-1β protein concen-
tration in culture supernatants of LPS-stimulated MKD-like THP-1 cells was measured using ELISA. Inserted 
figure is an enlarged view of the region at 3 μmol/L simvastatin and 1 ng/mL of LPS. Data are represented 
as mean + SD, n = 3. Statistical significance was determined by a Williams’ test with significance set at 
*P < 0.025 and **P < 0.005 (versus 0 nmol/L of TAK475 M-I in each experimental condition). ND: not detected
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P < 0.05 was considered statistically significant (Fig. 3). The cytotoxicity of simvastatin 
and LPS in THP-1 cells or the effects of GGPP and FPP in LPS-stimulated MKD-like 
THP-1 cells were evaluated by a Dunnett’s test. P < 0.05 was considered statistically sig-
nificant (Fig. 5).
Results
TAK‑475 M‑I significantly increased the levels of MDIs in THP‑1 cells
Effects of TAK-475  M-I on the level of four MDIs; FPP, FOH, GGPP and GGOH in 
human monocytic THP-1 cells were examined. THP-1 cells were treated for 48 h with 
0, 30, 100, 150, 300 and 1000  nmol/L of TAK-475  M-I. The concentrations of MDIs 
were calculated assuming that 106 THP-1 cell volume is equal to 970  μL (Kuijk et  al. 
2008). Levels of FPP and GGPP were increased by 48  h in a dose-dependent manner, 
whereas GGOH levels did not show any apparent changes (Fig. 1). Although there is a 
poor dose-dependency in FOH induction, a trend is observed in that high concentra-
tion of TAK-475 M-I can induce more FOH (Fig. 1). TAK-475 M-I potently inhibited de 
novo cholesterol synthesis in human primary hepatocytes with relative IC50 values of 
110 nmol/L (unpublished data). It should be obviously difficult to detect cholesterol level 
in human monocytic THP-1 cells compared with human hepatocytes because choles-
terol is mainly synthesized in the liver. If TAK-475 M-I can inhibit cholesterol synthesis 
in THP-1 cells like in human primary hepatocytes, TAK-475 M-I is suggested to be able 
to strongly increase FPP, FOH and GGPP with the effect against cholesterol inhibition.
MDIs blocked LPS‑stimulated IL‑1β production in MKD‑like THP‑1 cells
Effects of MDIs on LPS-stimulated IL-1β production in MKD-like human monocytic 
THP-1 cells were investigated. THP-1 cells were pretreated with simvastatin (4 μmol/L) for 
24 h in order to induce MKD-like phenotype by reducing endogenous MDI levels (Gale-
otti et al. 2012). The pretreated THP-1 cells were then treated with various concentrations 
of GGPP, GGOH, FPP, or FOH in the presence of LPS (10 ng/mL) for an additional 24 h. 
GGPP, GGOH and FPP showed dose-dependent suppression in IL-1β production in the 
culture supernatants (Fig.  2), and half maximum inhibitory concentration (IC50) values 
were 1.5, 369 and 1179 nmol/L, respectively (Table 1). Among these MDIs, GGPP had the 
most potent inhibitory effect. FOH did not show significant changes in IL-1β release. This 
study demonstrated that exogenous supply of GGPP, FPP and GGOH can strongly sup-
press LPS-induced IL-1β production in MKD-like THP-1 cells.
Table 1 The mean IC50 of  MDIs for  the inhibition of  LPS-stimulated IL-1β production 
in MKD-like THP-1 cells
ND not determined
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MDIs also reduced cytotoxicity in LPS‑stimulated MKD‑like THP‑1 cells
Effects of MDIs on cytotoxicity in LPS-stimulated MKD-like human monocytic THP-1 
cells were investigated. The treatment of 10 ng/mL of LPS increased DCR from approxi-
mately 20–35  % (Fig.  3). MDIs showed inhibitory effects against LPS-induced cyto-
toxicity in statin-treated THP-1 cells (Fig.  3). GGPP reduced LPS-induced DCR by 
approximately 70 % even at 1 μmol/L concentration, because 35 % DCR became 10 % 
DCR by shaving off 25 % worth of cytotoxicity which is about 70 % of LPS-induced DCR. 
FPP also reduced LPS-induced DCR by approximately 70  % at 10  μmol/L concentra-
tion. Moreover, other MDIs such as GGOH and FOH can also significantly reduce LPS-
induced cytotoxicity in MKD-like condition (Fig. 3).
These results has shown in Figs. 2 and 3 suggest that external supply of GGPP, FPP and 
GGOH suppresses the production of IL-1β without cytotoxicity.
MDIs blocked LPS‑stimulated IL‑1β production in MKD‑like human PBMCs
Effects of GGPP and FPP on LPS-stimulated IL-1β production in statin-treated human 
PBMCs were investigated. Human PBMCs were pretreated with simvastatin (3 μmol/L) 
for 24 h to induce an MKD-like phenotype by reducing endogenous MDI levels (Kuijk 
et  al. 2008), and then stimulated with LPS (200  ng/mL) in the presence of GGPP or 
FPP (10 μmol/L) for an additional 24 h. Both GGPP and FPP at 10 μmol/L significantly 
inhibited LPS-stimulated IL-1β production in MKD-like human PBMCs in all 3 donors 
(Fig. 4). It was obvious that GGPP had a much stronger inhibitory effect compared with 
FPP, confirming the IC50 value on Table 1 (Fig. 4).
MDIs also showed a tendency to reduce cytotoxicity in LPS‑stimulated MKD‑like human 
PBMCs
DCR of PBMCs increased with the treatment of simvastatin and LPS (Fig. 5). However, 
GGPP or FPP (10 μmol/L) showed a tendency to decrease the DCR in all donors. Judg-
ing from Figs. 4 and 5, both GGPP and FPP at 10 μmol/L significantly inhibited LPS-
stimulated IL-1β production without cytotoxicity in MKD-like human PBMCs.
TAK‑475 M‑I suppresses LPS‑stimulated IL‑1β production in both MKD‑like THP‑1 cells 
and human PBMCs
Effects of TAK-475  M-I on LPS-stimulated IL-1β production in statin-treated human 
monocytic THP-1 cells were investigated. THP-1 cells were treated with simvastatin (3 
or 4 μmol/L) to induce MKD-like phenotype by reducing endogenous MDI levels (Kuijk 
et al. 2008) and with TAK-475 M-I (150 or 1000 nmol/L) for 48 h, and then stimulated by 
LPS (0.1, 1 or 10 ng/mL) for additional 24 h. Both 150 and 1000 nmol/L of TAK-475 M-I 
significantly reduced LPS-stimulated IL-1β production in MKD-like THP-1 cells under 
the condition of 1  ng/mL LPS plus 3  μmol/L simvastatin (top-left balloon of Fig.  6). 
Similar trends were observed in other experimental conditions, but the effects were not 
always statistically significant under the condition of 0.1 or 10 ng/mL LPS (Fig. 6). Inhib-
itory effects of TAK-475 M-I at a concentration of 150 and 1000 nmol/L appeared to be 
comparable under the condition of 1 ng/mL LPS plus 3 or 4 μmol/L simvastatin (Fig. 6). 
This suggests that it reached a plateau even in 150 nmol/L. TAK-475 M-I did not show 
significant cytotoxicity in LPS-stimulated MKD-like THP-1 cells at a concentration of 
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1000 nmol/L (data not shown). Moreover, 1000 nmol/L of TAK-475 M-I reduced 41 % 
of LPS-stimulated IL-1β production even in MKD-like human PBMCs under the condi-
tion of 8 ng/mL LPS plus 3 μmol/L simvastatin (Fig. 7). These results suggest that TAK-
475 M-I also suppresses the production of IL-1β, which is one of causes of fever episode 
of MKD patients (Galeotti et al. 2012) without cytotoxicity.
Discussion
TAK-475 and its active metabolite M-I inhibit the enzyme that catalyzes the conversion 
of FPP to squalene on the cholesterol biosynthesis pathway. TAK-475 has been evalu-
ated extensively in both in vitro and in vivo experimental models that have confirmed 
cholesterol-lowering properties (Nishimoto et al. 2003; Amano et al. 2003). In patients 
with MKD, defective activity of the MK enzyme is hypothesized to lead to a shortage of 
MDIs such as FPP. Through squalene synthase inhibition in the cholesterol biosynthesis 
pathway, TAK-475 disrupts the conversion of FPP into squalene resulting in increased 
levels of FPP and other MDIs.
The effects of TAK-475 M-I on MDIs were examined in in vitro experiments. These 
results showed that treatment with TAK-475 M-I resulted in the significant increase of 
MDIs such as FPP, FOH, and GGPP in human monocytic THP-1 cell line, as shown in 
Fig. 1. In subsequent studies potential inhibitory effects of MDIs on IL-1β secretion were 
investigated in MKD-like conditions. THP-1 cells and PBMCs were first incubated for 
24 h with simvastatin, which inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) 
and thereby decreases levels of the precursors for MDI production (Bellosta et al. 2000), 
leading to MDI depletion as expected in MKD patients. The cells were then stimulated 
for 24 h with LPS, which induces IL-1β secretion, while in the presence of MDIs. Results 
from this study demonstrated that pretreatment of FPP, GGPP, and GGOH in a concen-
tration-dependent manner decreased LPS- induced IL-1β secretion in MKD-like THP-1 
Fig. 7 TAK-475 M-I inhibited LPS-stimulated IL-1β production in MKD-like human PBMCs. IL-1β protein con-
centration in culture supernatants of LPS-stimulated MKD-like human PBMCs was measured using ELISA. The 
experiment was conducted at 3 μmol/L simvastatin and 8 ng/mL of LPS. Data are represented as mean + SD, 
n = 3. Statistical significance was determined by a Dunnetts’ test with significance set at **P < 0.01 (vs. Con-
trol). ZAA: zaragozic acid A
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cell lines (Fig. 2). Similarly, GGPP and FPP both decreased LPS-induced IL-1β secretion 
in MKD-like human PBMCs regardless of the donor’s source (Fig.  4). The production 
of inflammatory cytokines such as IL-1β is considered as one of the causes of fever epi-
sodes in MKD patients (Galeotti et al. 2012). The increased levels of MDIs after treat-
ment with TAK-475 are therefore expected to mitigate the severity and/or frequency of 
fever episodes in patients with MKD.
According to the human plasma PK profile of TAK-475, oral administration of TAK-
475 100  mg once daily leads to the average plasma concentration of approximately 
30 nmol/L of total active concentration of TAK-475 and its active metabolites (data not 
shown). Therefore, based on the detailed data in Fig. 1, it is anticipated that 30 nmol/L 
of TAK-475 can induce approximately 427 µmol/L of FPP and approximately 88 µmol/L 
of GGPP in THP-1 cells. The anticipated increase in levels of MDIs may be much less in 
MKD patients compared to healthy human subjects because of very limited availability 
of isopentenyl pyrophosphate (IPP). However, given that the mean inhibitory concentra-
tions (IC50) of FPP and GGPP are very low at 1.18 µmol/L and 1.5 nmol/L, respectively, 
in MKD-like THP-1 cells (Table 1), a slight increase in FPP and GGPP levels induced by 
TAK-475 100  mg may give sufficient inhibition of IL-1β production in MKD patients 
and mitigate fever episodes. Moreover, treatment with TAK-475 M-I was confirmed to 
inhibit IL-1β production in THP-1 cell lines exhibiting an MKD-like phenotype in 35 % 
reduction at 150 nmol/L and 23 % reduction at 1000 nmol/L (Fig. 6). It is also confirmed 
that TAK-475  M-I can inhibit IL-1β production even in MKD-like human PBMCs in 
41 % reduction at 1000 nmol/L (Fig. 7). Increased MDIs by TAK-475 treatment would 
be able to block the production of inflammatory cytokines, which is one of the causes 
of fever episodes in MKD patients, in the clinical setting (Marcuzzi et  al. 2013; Gale-
otti et al. 2012). Similarly, Kuijk et al. (2008) showed that the addition of GGPP led to a 
decrease in levels of IL-1β in THP-1 cell lines that were treated with simvastatin to pro-
duce MKD-like inflammatory phenotype.
Interestingly, MDIs have significant cytoprotective effects in LPS-stimulated THP-1 
cells, which are treated with simvastatin to induce an MKD-like phenotype. It is reported 
that statins induce apoptosis via caspase-3 activation in glioma cells (Yanae et al. 2011). 
As LPS stimulation is also known to induce apoptosis in some endothelial cells, it would 
be reasonable that LPS treatment enhanced DCR 75 % more in MKD-like THP-1 cells 
by changing from 20 % DCR into 35 % DCR (Fig. 3). This DCR was most significantly 
inhibited by GGPP as shown Fig. 3. This might be due to the inhibition caspase-3 activ-
ity via ERK1/2 and Akt activations because the supplementation of MDIs such as GGPP 
is reported to enhance both Ras-ERK1/2 and Ras-Akt signaling pathways (Yanae et al. 
2011). Similarly, the supplementation of both GGPP and FPP decreased LPS-induced 
DCR in statin-treated human PBMCs (Fig.  5). These results suggested that TAK-475 
could recover the damaged cells of MKD patients, which were caused by the decreases 
levels of the precursors for MDI production.
Our results suggest that TAK-475  M-I can block the production of inflammatory 
cytokine IL-1β as well as significantly enhanced the cytoprotective effect in MKD-like 
human immune cells, indicating that TAK-475 has a potential to be the disease modify-
ing drug in patients with MKD.
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Conclusion
In this study, we have demonstrated the anti-inflammatory and cytoprotective poten-
tials of TAK-475 M-I, benzoxazepine derivative SSI, through the accumulation of MDIs 
in immune cells simulating MKD-like condition. As the shortage of MDIs could be the 
main cause of MKD symptoms such as fever episodes, the disease-modifying therapeu-
tic effects will be expected by TAK-475 treatment in MKD patients.
Authors’ contributions
Conceived and designed the experiments: NS TI HM MT. Performed the experiments: NS TI. Analyzed the data: NS TI HM 
MT. Contributed reagents/materials/analysis tools: NS TI. Wrote the paper: NS. All authors read and approved the final 
manuscript.
Acknowledgements
We are grateful to Drs. Michie Hisada and Saurabh Gupta for critical reading of the manuscript and useful feedbacks. 
We thank Drs. Tauhid Ali, Richard Philipson, Guido Hanauer, Takuya Ebihara, Shotaro Miura, Hideo Fukui, Kok Wah Hew, 
Katsunori Takashima, Taku Sugita, Masatoshi Karashima, and Fumihiro Jinno for fruitful discussions. Special thanks go to 
Dr. Ryuichi Tozawa for help and useful suggestions.
Competing interests
The authors declare that they have no competing interests.
Received: 9 February 2016   Accepted: 23 August 2016
References
Amano Y, Nishimoto T, Tozawa R, Ishikawa E, Imura Y et al (2003) Lipid-lowering effects of TAK-475, a squalene synthase 
inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol 466:155–161
Bader-Meunier B, Florkin B, Sibilia J, Acquaviva C, Hachulla E et al (2011) Mevalonate kinase deficiency: a survey of 50 
patients. Pediatrics 128:e152–e159
Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A (2000) Non-lipid-related effects of statins. Ann Med 32:164–176
Esposito S, Ascolese B, Senatore L, Bosis S, Verrecchia E et al (2014) Current advances in the understanding and treatment 
of mevalonate kinase deficiency. Int J Immunopathol Pharmacol 27:491–498
Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-Meunier B et al (2012) Efficacy of interleukin-1-targeting drugs 
in mevalonate kinase deficiency. Rheumatology (Oxford) 51:1855–1859
Hubner C, Hoffmann GF, Charpentier C, Gibson KM, Finckh B et al (1993) Decreased plasma ubiquinone-10 concentration 
in patients with mevalonate kinase deficiency. Pediatr Res 34:129–133
Kostjukovits S, Kalliokoski L, Antila K, Korppi M (2015) Treatment of hyperimmunoglobulinemia D syndrome with biolog-
ics in children: review of the literature and Finnish experience. Eur J Pediatr 174:707–714
Kuijk LM, Mandey SH, Schellens I, Waterham HR, Rijkers GT et al (2008) Statin synergizes with LPS to induce IL-1beta 
release by THP-1 cells through activation of caspase-1. Mol Immunol 45:2158–2165
Lainka E, Neudorf U, Lohse P, Timmann C, Bielak M et al (2012) Incidence and clinical features of hyperimmunoglobu-
linemia D and periodic fever syndrome (HIDS) and spectrum of mevalonate kinase (MVK) mutations in German 
children. Rheumatol Int 32:3253–3260
Liao YH, Lin YC, Tsao ST, Lin YC, Yang AJ et al (2013) HMG-CoA reductase inhibitors activate caspase-1 in human mono-
cytes depending on ATP release and P2X7 activation. J Leukoc Biol 93:289–299
Mandey SH, Kuijk LM, Frenkel J, Waterham HR (2006) A role for geranylgeranylation in interleukin-1beta secretion. Arthri-
tis Rheum 54:3690–3695
Marcuzzi A, Zanin V, Kleiner G, Monasta L, Crovella S (2013) Mouse model of mevalonate kinase deficiency: comparison 
of cytokine and chemokine profile with that of human patients. Pediatr Res 74:266–271
Miki T, Kori M, Mabuchi H, Tozawa R, Nishimoto T et al (2002) Synthesis of novel 4,1-benzoxazepine derivatives as 
squalene synthase inhibitors and their inhibition of cholesterol synthesis. J Med Chem 45:4571–4580
Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y et al (2003) Lipid-lowering properties of TAK-475, a squalene syn-
thase inhibitor, in vivo and in vitro. Br J Pharmacol 139:911–918
Schneiders MS, Houten SM, Turkenburg M, Wanders RJ, Waterham HR (2006) Manipulation of isoprenoid biosynthesis as 
a possible therapeutic option in mevalonate kinase deficiency. Arthritis Rheum 54:2306–2313
Stein EA, Bays H, O’Brien D, Pedicano J, Piper E et al (2011) Lapaquistat acetate: development of a squalene synthase 
inhibitor for the treatment of hypercholesterolemia. Circulation 123:1974–1985
Ter Haar N, Lachmann H, Woo P, Simon A, Dolezalova P et al (2013) PReS-FINAL-2335: preliminary analysis of 85 patients 
with mevalonate kinase deficiency from the eurofever registry. Pediatr Rheumatol 11:P325
Tricarico PM, Kleiner G, Valencic E, Campisciano G, Girardelli M et al (2014) Block of the mevalonate pathway triggers 
oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds. Int J Mol Sci 
15:6843–6856
van der Burgh R, Ter Haar NM, Boes ML, Frenkel J (2013) Mevalonate kinase deficiency, a metabolic autoinflammatory 
disease. Clin Immunol 147:197–206
Page 14 of 14Suzuki et al. SpringerPlus  (2016) 5:1429 
van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP et al (2008) Long-term follow-up, clinical features, and quality of 
life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 87:301–310
Xu N, Shen N, Wang X, Jiang S, Xue B et al (2015) Protein prenylation and human diseases: a balance of protein farnesyla-
tion and geranylgeranylation. Sci China Life Sci 58:328–335
Yanae M, Tsubaki M, Satou T, Itoh T, Imano M et al (2011) Statin-induced apoptosis via the suppression of ERK1/2 and Akt 
activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res 
30:74
